Clinical trial
"SINT1A" - Supplementation With B. Infantis for Mitigation of Type 1 Diabetes Autoimmunity - A Study of the Global Platform for the Prevention of Autoimmune Diabetes ("GPPAD")
NCT04769037 is registered in ClinicalTrials.gov with Helmholtz Zentrum München as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- "SINT1A" - Supplementation With B. Infantis for Mitigation of Type 1 Diabetes Autoimmunity - A Study of the Global Platform for the Prevention of Autoimmune Diabetes ("GPPAD")
- Lead sponsor
- Helmholtz Zentrum München
- Phase
- Not applicable
- Overall status
- Active, not recruiting
- Start date
- April 22, 2021
- Completion date
- October 31, 2027
- Enrollment
- 1,149 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.